Pierluigi Paracchi, CEO and Co-founder Genenta Science
Richard Slansky, CFO Genenta Science
Hosted by Genenta Science
Moderated by Brad Loncar
In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno gene & cell therapy as a potential treatment for glioblastoma and other solid tumors. Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients.
Brad Loncar (CEO of Loncar Investments) will serve as the fireside chat moderator and Carlo Russo, MD (Genenta CMO & Head of Development) will also participate in the discussion.
A live question and answer session will follow.
Speaker: Stefania Mazzolone Ph.D Scientifica Project Manager and Communication Officier
The workshop will be held both in presence (by invitation only) and online In person event at MIND – Milan Innovation District
Speaker Carlo Russo, Chief Medical Officer & Head of Development Genenta Science
Speaker Pierluigi Paracchi, CEO & Co-Founder Genenta Science
24th February 2022 at 3-4,5 pm
Speaker: Pierluigi Paracchi CEO and co-founder Genenta Science
Speaker: Pierluigi Paracchi CEO and CO-Founder Genenta Science